X4 Pharmaceuticals (XFOR) Cash & Current Investments (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted Cash & Current Investments of $217.0 million for Q4 2025, up 211.71% on a QoQ basis from $69.6 million in Q3 2025, and up 289.68% year-over-year from $55.7 million in Q4 2024.
X4 Pharmaceuticals (XFOR) Cash & Current Investments (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' Cash & Current Investments history runs 9 years deep, the most recent figure standing at $217.0 million for Q4 2025.
- Quarterly Cash & Current Investments rose 289.68% year-over-year to $217.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $217.0 million (up 289.68% YoY) and the FY2025 annual result came in at $217.0 million, up 289.68% from the prior year.
- Cash & Current Investments was $217.0 million for Q4 2025 at X4 Pharmaceuticals, up from $69.6 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $217.0 million in Q4 2025 and bottomed at $39.2 million in Q2 2025.
- A 5-year average of $93.6 million and a median of $87.6 million in 2021 frame the typical range for Cash & Current Investments.
- Peak annual rise in Cash & Current Investments reached 289.68% in 2025, while the deepest fall reached 73.36% in 2025.
- X4 Pharmaceuticals' Cash & Current Investments stood at $81.8 million in 2021, then surged by 48.82% to $121.7 million in 2022, then decreased by 18.49% to $99.2 million in 2023, then sank by 43.86% to $55.7 million in 2024, then soared by 289.68% to $217.0 million in 2025.
- Business Quant data shows XFOR's Cash & Current Investments at $217.0 million in Q4 2025, $69.6 million in Q3 2025, and $39.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | 217.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 217.05 Mn |
| Sep 30, 2025 | 69.63 Mn |
| Jun 30, 2025 | 39.22 Mn |
| Mar 31, 2025 | 40.26 Mn |
| Dec 31, 2024 | 55.70 Mn |
| Sep 30, 2024 | 97.41 Mn |
| Jun 30, 2024 | 147.22 Mn |
| Mar 31, 2024 | 60.49 Mn |
| Dec 31, 2023 | 99.22 Mn |
| Sep 30, 2023 | 131.58 Mn |
| Jun 30, 2023 | 136.43 Mn |
| Mar 31, 2023 | 93.40 Mn |
| Dec 31, 2022 | 121.72 Mn |
| Sep 30, 2022 | 79.86 Mn |
| Jun 30, 2022 | 47.38 Mn |
| Mar 31, 2022 | 66.40 Mn |
| Dec 31, 2021 | 81.79 Mn |
| Sep 30, 2021 | 76.40 Mn |
| Jun 30, 2021 | 95.20 Mn |
| Mar 31, 2021 | 114.90 Mn |